Earnings
Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.
Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.
Photys Therapeutics launched Thursday with $75 million in financing and a focus on developing phosphorylation-inducing chimeric small molecule medicines to target underserved diseases.
SpringWorks announced the expansion of its partnership with GlaxoSmithKline to develop nirogacestat in combination with GSK’s Blenrep for relapsed or refractory multiple myeloma.
Arcutis scoops up Ducentis and its lead asset DS-234, UC San Diego receives $150M earmarked for stem cell, regenerative medicine research and Arsenal and ILiAD reel in new funds.
Provention Bio secured a $125 million loan from Hercules Capital that will support operations and the potential launch of the company’s type 1 diabetes treatment, teplizumab.
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
PRESS RELEASES